Thermo Fisher Scientific Expands Pharma Division in Greenville, North Carolina
03/20/2019
According to company officials the expansion will provide additional capacity for sterile liquid and lyophilized product development and commercial manufacturing.
Included in the site expansion projects are Monza and Ferentino, Italy, and Greenville, North Carolina. In response to customer requests, each of the sites will be equipped with aseptic filling lines and isolator technology. Construction is expected to be completed within the next 24 months.
"These investments will help expand our global sterile manufacturing network and meet the increasing demand from customers that rely on our biologics development and manufacturing expertise," said Michel Lagarde, President of pharma services for Thermo Fisher Scientific.
"We continue to invest to expand our capabilities and help our customers deliver the highest quality medicines to the patients who need them,” Lagarde added.
Project Announcements
Contec Industrial Automation Solutions Plans Greensboro, North Carolina, Operations
01/21/2025
Canada-Based Cardiff Products Plans West Columbia, South Carolina, Beverage Packaging Operations
01/17/2025
Messer Plans Berryville, Arkansas, Air Separation Operations
01/16/2025
NewGlobal Ventures Plans Estancia Valley, New Mexico, Canning Operations
01/16/2025
Oxeon Energy Expands Davis County, Utah, Production Operations
01/13/2025
Nucor Towers & Structures Plans Brigham City, Utah, Production Operations
01/13/2025
Most Read
-
2024's Leading Metro Locations: U.S. Cities on the Rise Amid an Economic Reshuffling
Q4 2024
-
The Workforce Factor: How States Are Competing to Build Tomorrow's Talent
Q4 2024
-
Best Practices in Incentives Procurement
Q4 2024
-
Five Strategies to Tackle the Data Center Talent Shortage
Q4 2024
-
Microsoft-Three Mile Island Deal Could Signal Path for Nuclear Power to Strengthen Partnerships with Big Tech
Q4 2024
-
Why Decarbonization Goals Start with Site Selection
Q4 2024
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024